Influenza A virus H7N9 vaccine - Novavax

Drug Profile

Influenza A virus H7N9 vaccine - Novavax

Alternative Names: A (H7N9) vaccine - Novavax; A(H7N9) influenza vaccine candidate - Novavax; H7N9 Virus-Like Particle (VLP) Influenza vaccine (recombinant) - Novavax; H7N9 VLP vaccine - Novavax; Monovalent VLP influenza H7N9 vaccine - Novavax; Pandemic H7N9 + Matrix-M™ influenza vaccine; Pandemic H7N9 Influenza VLP vaccine

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Novavax
  • Class Influenza A virus H7N9 vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza A virus H7N9 subtype

Most Recent Events

  • 06 Sep 2016 Phase-II clinical trials in Influenza-A virus H7N9 subtype (Prevention) in USA (IM) before September 2016 (Novavax pipeline, September 2016)
  • 30 Jul 2015 Novavax plans a phase II trial for Influenza-A virus H7N9 subtype (Prevention)
  • 01 Jul 2015 Novavax completes a phase I/II trial in Influenza-A virus H7N9 subtype (Prevention) in USA (NCT02078674)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top